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Prakash Parajuli1†, Ramesh Prasad Pandey1†, Niranjan Koirala1, Yeo Joon Yoon2, Byung-Gee Kim3 and Jae Kyung Sohng1*Abstract
Epothilones are extremely cytotoxic chemotherapeutic agents with epoxide, thiazole, and ketone groups that share
equipotent kinetic similarity with taxol. The in vitro glycosylation catalyzed by uridine diphosphate
glucosyltransferase (YjiC) from Bacillus licheniformis generated six novel epothilone A glycoside analouges including
epothilone A 7-O-β-D-glucoside, epothilone A 7-O-β-D-galactoside, epothilone A 3,7-O-β-D-digalactoside, epothilone
A 7-O-β-D-2-deoxyglucoside, epothilone A 7-O-β-L-rhamnoside, and epothilone A 7-O-β-L-fucoside. Epothilone A
7-O-β-D-glucoside was structurally elucidated by ultra-high performance liquid chromatography-photo diode array
(UPLC-PDA) conjugated with high resolution quantitative time-of-flight-electrospray ionization mass spectroscopy
(HR-QTOF ESI-MS/MS) supported by one-and two-dimensional nuclear magnetic resonance studies whereas other
epothilone A glycosides were characterized by UPLC-PDA and HR-QTOF ESI-MS/MS analyses. The time dependent
conversion study of epothilone A to epothilone A 7-O-β-D-glucoside found to be maximum (~26%) between 3 h to
5 h incubation.
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Epothilones are a class of polypeptide macrolides produced
by a few strains of myxo-bacterium such as Sorangium
cellulosum (Cheng et al. 2008). Epothilones are structurally
characterized as macrolactones with epoxy and keto-
groups in a lactone ring and a side chain with a thiazole
ring (Figure 1). Epothilones were discovered in 1987 as
antifungal agents (Hofle and Reichenbach 2005). Different
analogs of epothione (A–H) containing 29 variants have
been reported in S. cellulosum but epothilone A and B are
the major products with potential applications in therapy
and cytotoxic effect in tumor cell lines (Hardt et al. 2001).
Similarly, 37 natural epothilone variants and related com-
pounds were later isolated and confirmed from the same
strain by Hofle and Reichenbach in 2001.
Eothilones have been recognized as chemotherapeutic
agents against different tumor cell lines including those
affected by taxanes with manageable toxicity profiles
demonstrated in both preclinical and clinical trials (Lee
et al. 2001; Thomas et al. 2007). Eothilones are potent
inducers of a microtubule stabilizing agent, which binds* Correspondence: sohng@sunmoon.ac.kr
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in any medium, provided the original work is pto β-tubulin during mitotic cell division, resulting in
apoptosis or programmed cell death (Lee et al. 2007).
Although paclitaxel (taxol) appears to be the most effective
antineoplastic agent in the last decade, but it has several
drawbacks such as poor solubility and the use of cremo-
phor (solubilizing agent, causes side effects via hyperlipid-
emia and abnormal lipoprotein patterns) (Rowinsky et al.
1993) which leads in search of novel antibiotics. This
hurdle has been cleared by introducing epothilones with
higher potency against tumor cells including more water
soluble properties, and can be administered without any
additives compare to paclitaxel (Bollag et al. 1995). Fur-
thermore, the in vivo cytotoxic activity of epothilone A
and B compared with that of paclitaxel against various
multi-drug resistances cancer cell lines has also been
reported (Carlomagno et al. 2003).
Natural products have long been a source of cancer
therapeutic agents. Therefore, it is a continual need of
anticancer drug discovery and their modifications either
structurally or functionally to enhance the therapeutic
applications (Padilla and Furlan 2009). Enzymatic synthesis
and modification of such natural products is a current need
to significantly enhance their pharmacological properties
and biological actions (Luzhetskyy and Bechthold 2008;
Thibodeaux et al. 2008). The majority of natural products
have carbohydrate attached, that helps in cell recognitionan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Typical structure of epothilone. The structure displays
thiazole ring, ketone group and an epoxide ring in epothilone group
of compounds.
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cell integrity, molecular recognition, pathogen virulence,
and molecular defense mechanism (Song et al. 2013; Singh
et al. 2012). Glycosylation as a post-modification process is
an effective tool to diversify natural products (Simkhada
et al. 2010). Glycosylation broadens the biological potency
and applications of compounds by altering physical, chem-
ical, and biological properties (Singh et al. 2012). For
example, paclitaxel i.e. 7-β-xylosyl-10 deacetyltaxol, a
glycoconjugate of the taxane prodrug, has more than two
orders of magnitude improved water solubility without a
reduction in clinical efficacy. The similar property was
shown with water solubility of geldanamycin analogs (Wu
et al. 2012; Cheng et al. 2013) as the clinical utility of gel-
danamycin has been compromised, although it is a potent
anticancer drug due to its poor water solubility and severe
toxic effects (Wu et al. 2012). Many such hurdles have
been overcome through the use of glycosylated analogues
which are difficult to obtain from the parent compound
(Lomino et al. 2013). Most natural products currently
used as therapeutics derive their biological functions from
the sugar components present in their structure; however,
alterations could broaden their pharmacological properties
(Chang et al. 2011). For example, the DNA binding affinity
and cytotoxicity of rebeccamycin (an antitumor drug
with potential topoisomerase I poisoning effects) can
be altered by variation in sugar moieties (Animati et al.
2008). Doxorubicin (similar antitumor agent with strong
chemotherapeutic applications) has no antitumor activity
if the sugar moiety is removed (Han et al. 2011); and
tylosin and erythromycin (antibiotics) have sugar moi-
eties that may affect their molecular mechanism of action
(Langenhan et al. 2005). Amphotericin B (an antifungal
agent) has a glycoside attached that enhances its solubility
and pharmacokinetics (Elgart et al. 2010).Glycosylation is defined as coupling of a sugar moiety
with an aglycone acceptor, which can be achieved by
enzymatic, chemical synthesis, and chemoenzymatic ap-
proaches (neo-glycosylation). The first approach is cata-
lyzed by enzymes called UDP-glycosyltransferases, which
belong to the GT1 family proteins in the CAZy classifi-
cation (http://www.cazy.org/). Carbohydrate moieties are
usually attached to molecules via the O-glycosidic bond
but some are linked through C– or N-glycosidic linkages
(Salas and Mendez 2007). The number and type of
conjugated sugar units on the compound depends on the
enzyme used for catalysis.
Here, we generated epothilone A glycoside analogues
by applying a YjiC from Bacillus licheniformis DSM 13.
YjiC conjugates different sugar units in plant natural
products with low molecular weight, including chalcone
(Pandey et al. 2013a), flavonols (Pandey et al. 2013b) and
potential anticancer drugs such as geldamycin (Wu et al.
2012). In this study, we explored the macrolide epothilone
A, as an aglycon substrate and different nucleotide di-
phosphate sugars (NDP-D/L-sugars) as sugar donors to
generate novel epothilone A glycoside derivatives.
Materials and methods
Chemicals and reagents
Epothilone A was available in the laboratory (Samyang
Genex Co., Korea). UDP-D-glucose and UDP-D-galactose
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA). TDP-D-2-deoxyglucose, TDP-L-rham-
nose, and GDP-L-fucose were obtained from GeneChem
(Daejeon, South Korea). High performance liquid chroma-
tography (HPLC) grade methanol and water were purchased
from Mallinckrodt Baker (Phillipsburg, NJ, USA). The
remaining chemicals were high-grade products purchased
from commercially available sources.
Plasmid, microorganisms, and culture conditions
A previously constructed pET28 (a)-YjiC (Pandey et al.
2013a) plasmid was used for transformation in the E. coli
BL21 (DE3) (Stratagene, La Jolla, CA, USA) expression host
for protein production. E. coli BL21 (DE3) harboring the
pET28 (a)-YjiC strain was grown in Luria- Bertani (LB)
liquid medium. The culture was incubated at 37°C with
kanamycin (50 μg/mL) supplementation when required.
Expression and purification of glycosyltransferase
A single transformant of E. coli BL21(DE3) harboring
pET28 (a)-YjiC was cultured overnight in a shaking incu-
bator in 37°C and 150 rpm. 500 μL of seed culture was
transferred to fresh 50 mL LB medium supplemented
with 50 μg/mL kanamycin. Once the optical density at
600 nm reached 0.6, the culture was induced with a 0.8 mM
final concentration of isopropyl-β-D-thiogalactopyranoside
and incubated for 20 h at 20°C in shaking incubator at
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gation at 3,000 rpm for 15 min and washed (vortex
followed by centrifugation) with buffer (50 mM
Tris–HCl and 10% glycerol of pH 7.4) two times and re-
suspended in 1 mL of the same buffer. The cells were son-
icated, and the clear lysate was collected by high speed
centrifugation at 12,000 rpm for 30 min at 4°C. The
clear lysate thus obtained was packed into a His-
TALON metal nickel affinity resin (Takara Bio, Shiga,
Japan) for 30 min at 4°C. The resin-bound protein was
eluted step by step by gravity flow with increasing concen-
trations of imidazole (10 mM, 100 mM, and 200 mM in
buffer containing 200 mM NaCl and 20 mM Tris–HCl,
pH 7.4). Fractions containing purified protein were ana-
lyzed by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and further concentrated
using Amicon Ultra-15 filters (Millipore, 30 K NMWL de-
vice; Milford, MA, USA). The purified and concentrated
protein was stored in buffer containing 50 mM Tris–HCl,
pH 7.4, and 10% glycerol at −20°C.
In vitro reaction conditions
The glycosylation reaction was carried out under two
conditions using purified protein (YjiC) with the epothi-
lone A and UDP-D-glucose, UDP-D-galactose, TDP-D-
2-deoxyglucose, TDP-L-rhamnose, and GDP-L-fucose as
sugar donors. A lab-scale reaction was conducted using a
100 μL reaction volume and maintaining a final concen-
tration of 50 mM Tris–HCl buffer at pH 7.4, 10 mM
MgCl2 6H2O, 2 mM substrate (dissolved in Dimethyl sulf-
oxide (DMSO)) and 4 mM NDP-sugars individually with
30 μg/mL of appropriately diluted enzyme, and the
remaining volume was Milli-Q distilled water. The mixture
was incubated at 37°C for 3 h and quenched by adding
300 μL chilled methanol (HPLC grade). The reaction mix-
ture without enzyme was kept as a control. The reaction
mixtures were centrifuged at 12,000 rpm for 20 min to re-
move protein precipitates. Thus, the mixture was finally an-
alyzed by UPLC-PDA and HR-QTOF ESI-MS analyses.
The preparative-scale reaction was carried out in a 5 mL
volume with purified YjiC (300 μg/mL), 8 mM UDP-D-
glucose (~49 mg), 5 mM substrate (~12.3 mg, dissolved in
DMSO), 50 mM Tris–HCl (pH 7.4) buffer, and 10 mM
MgCl2 and incubated for 18 h at 37°C. The reaction was
stopped by adding a triple volume of chilled methanol.
The reaction mixture was continuously mixed by vortex
followed by centrifugation at 12,000 rpm for 30 min at
4°C to remove the denatured protein. The supernatant
was concentrated by evaporation and lyophilization.
Analytical procedures
The reaction mixture was analyzed by reverse-phase
UPLC-PDA with a C18 column (ACQUITY UPLC® BEH,
C18, 1.7 μm) connected to a PDA (UPLC LG 500 nm) at aUV absorbance of 249 nm. The binary mobile phases were
composed of solvent A (HPLC grade water) and solvent B
(100% methanol, MeOH). Total flow rate was maintained
at 0.4 μL/min for the 10 min program. Flow of B (MeOH)
was 0% to 5 min and increased to 100% until 8 min
followed by constant flow of 0% at 8–10 min and then
flow was stopped at 10 min. The HR-QTOF ESI-MS ana-
lysis was performed in positive ion mode on an ACQUITY
(UPLC, Waters Corp., Billerica, MA, USA) column coupled
with SYNAPT G2-S (Water Corp).
The dried preparative scale reaction product was finally
purified by preparative HPLC (Shimadzu, Tokyo, Japan)
with a C18 column (YMC-Pack ODS-AQ (150 × 20 mm I.
D., 10 μm) connected to a UV detector at a UV absorbance
of 249 nm using a 46 min binary program with flow of solv-
ent B (100% MeOH) and A (HPLC grade water). Flow of B
was initially maintained at 20% and increased to 75% until
25 min, 90% remained (25–35 min) and then flow was
decreased to 50% at 40 min followed by 20% at 45 min and
finally stopped at 46 min with a flow rate of 10 ml/min.
The product was dried, lyophilized, dissolved in
methanol-d4, and subjected to 900 MHz Bruker, BioSpin
nuclear magnetic resonance (NMR) analysis including one-
dimensional 1H NMR, 13C NMR, and two-dimensional
NMR-correlation Spectroscopy (COSY), rotating-frame
nuclear Overhauser effect spectroscopy (ROESY), hetero-
nuclear single quantum coherence (HSQC), and heteronuc-
lear multiple bond connectivity (HMBC) when appropriate.
Results
Expression and purification of glycosyltransferase
The recombinant enzyme YjiC (GenBank accession number
AAU40842) was heterologously expressed in E. coli BL21
(DE3) soluble fraction as an N-terminal hexahistidine-
tagged fusion protein. The crude protein was purified
using nickel affinity chromatography. SDS-PAGE analysis
of the protein produced a distinct band corresponding
to hexahistidine-tagged YjiC as in our previous report
(Pandey et al. 2013a,b). The purified protein was used
for further glycosylation experiments.
Enzymatic synthesis of the epothilone A glucoside
The purified YjiC enzyme was incubated with epothilone
A and UDP-D-glucose in a lab-scale reaction mixture at
37°C for 3 h. The UPLC-PDA chromatogram analysis of
the reaction mixture showed a novel peak at a retention
time (tR) of 3.51 min (Figure 2(A)). The novel peak was
further analyzed by UPLC-PDA coupled with HR-QTOF
ESI-MS. The mass analysis identified epothilone A glu-
coside in the reaction mixture ([EpoAGlu + H]
+ m/z+:
calculated exact mass 656.3105 for C32H50NO11S, found
656.3079, Figure 3(A)). A preparative scale reaction
was carried out to further elucidate the structure of the
epothilone A glucoside. The preparative scale reaction
Figure 2 UPLC-PDA analyses of epothilone A reaction mixture with different sugar donors revealed the new peak(s) generating their
respective glycosides as novel compounds. The chromatogram (A) represents the reaction mixture with UDP-D-glucose; (B) TDP-D-2-deoxyglucose;
(C) UDP-D-galactose, (D) GDP-L-fucose, and (E) and TDP-L-rhamnose with epothilone A. Reaction mixture with UDP-D-galactose generated two novel
peaks and has been identified as mono-galactoside and di-galactoside of epothilone A. The triangle shape symbol represents epothilone A aglycon
standard whereas the filled diamond shape symbols represent the peaks of rare sugars conjugated epothilone A glycosides.
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lone A (5 mM, ~12.3 mg, dissolved in DMSO) resulted
in the production of (~1.3 mM, ~4.26 mg) of epothilone
A glucoside representing a ~26 % conversion of epothi-
lone A in the single reaction mixture. The reaction
product was purified by prep-HPLC, and the dried
product was characterized using various NMR studies.
Epothilone A had two reactive hydroxyl positions at C-3
and C-7. The YjiC glycosyltransferase transfers the sugar
moiety to any of the two hydroxyl groups available. Our
previous studies have shown that YjiC transfers the
sugar moiety non-regiospecifically to different available
hydroxyl positions of flavonoids (Pandey et al. 2013a,
b). Thus, the sugar could be coupled with either of the
C-3 or C-7 positions of epothilone A.
Structural elucidation of epothilone A glucoside
One-dimensional NMR (1D-NMR, 1H NMR) and two-
dimensional NMR (2D-NMR, 1H- 1H COSY, ROESY,HMBC, and HSQC) analyses were carried out to elucidate
the structure of epothilone A glucoside. The 1H NMR
study of the purified reaction product showed the presence
of an anomeric proton at the chemical shift δ = 4.49 ppm
(d, J = 7.8 Hz, 1H, H-1'), representing an anomeric proton
with a beta (β) configuration of the sugar moiety, whereas
other spectra were observed in the sugar region between
δ = (3.0–4.0) ppm (Figure 4). Other protons of the epothi-
lone A standard and their products matched exactly when
compared with the 1H NMR of epothilone as shown in
Table 1, Additional file 1: Figure S1 and S2. 2D-NMR ana-
lyses were carried out to further confirm the glucosylation
position. The 1H–1H COSY NMR analysis (Additional
file 1: Figure S2 (B)) showed that the anomeric proton
(δ= 4.49 ppm) was in a close relationship with δ = 3.2 ppm,
which was annotated to H-6 of epothilone by comparing
our data with 1H NMR of previously identified epothilone
A and pentoside of epothilone as epothiloneoside A by
Zhao et al. 2010. Different hydroxylated and epoxidated
Figure 3 The UPLC-PDA coupled with HR-QTOF ESI-MS analysis. Different epothilone A glycosides presenting their respective mass in reference
to the aglycon mass [EpoA + H]+ m/z+ ~ 494.2576 are as follows: (A) Epothilone A 7-O-β-D-glucoside [EpoAGlc + H]+ m/z+ ~ 656.3079, (B) Epothilone A
7-O-β-D-2-deoxyglucoside [EpoA2-deoxyglc + H]+ m/z+ ~ 640.3226, (C) Epothilone A 7-O-β-D-galactoside [EpoAGal + H]+ m/z+ ~ 656.3265, (D) Epothilone
A 3, 7-O-β-D-digalactoside [EpoADigal + H]+ m/z+ ~ 818.3639, (E), Epothilone A 7-O-β-D-fucoside [EpoAfuc + H]+ m/z+ ~ 640.3170 and (F) Epothilone A
7-O-β-D-rhamnoside [EpoArhm + H]+ m/z+ ~ 640.3147.
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transformation using Aspergillus niger (Wang et al. 2009)
which were characterized by different NMR analyses.
Similarly, the ROESY-NMR analysis showed a correl-
ation between the anomeric proton (H-1') and H-24
(δ= 1.30), H-6 (δ = 3.29), H-2' (δ = 3.41), and H-7 (δ = 3.83)providing a clue regarding the attachment of a sugar in
the C-7 hydroxyl group of epothilone A (Additional file 1:
Figure S2 (D)). These results were further supported by
HSQC and HMBC analyses showing the correlation of
protons with carbons. The HSQC analysis (Additional
file 1: Figure S2 (F)) revealed a correlation between H-1'
Figure 4 1H NMR comparison of epothilone A 7-O-β-D-glucoside and epothilone A standard. The NMR analysis shows anomeric proton
position and sugar region of the glucoside derivative of epothilone A.
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103 ppm and C-7 of epothilone (δ = 74.48) distinctly.
Similarly, the HMBC analysis (Additional file 1: Figure S2
(H)) showed a close correlation between the anomeric
carbon (C-1', δ = 103), H-7 (δ = 3.83), and H-6 (δ = 3.2),Table 1 Comparison of 1H NMR of epothilone A standard with
No. 1H NMR of epothilone
A standard
1H NMR of epothilone
A 7-O-β-D glucoside
2a 2.58 (dd, 14.5, 10.4, 1-H) 2.60 (d, 4.5, 1-H)
2b 2.44 (dd, 14.4, 3.3, 1-H) 2.40-2.24 (m, 1-H)
3 4.22 (dd, 10.4, 3.3, 1-H) 4.31 (dd, 9.1, 4.9)
4 No proton No proton
6 3.26 (qd, 6.8, 4.7, 1-H) 3.29 (ddd, 9.7, 5.5, 2.5, 1-H)
7 3.83 (t, 4.4, 1-H) 3.83 (dd, 5.7, 2.1, 1-H)
8 1.84-1.70 (m, 2-H) 1.67-1.60 (m, 2-H)
9 1.53-1.42 (m, 2-H) 1.48-1.34 (m, 4-H)
10a 1.66-1.52 (m, 1-H) 1.56 (dtd, 12.0, 7.6, 4.5, 1H)
10b 1.53-1.42 (m, 1-H) 1.48-1.34 (m, 4-H)
11a 1.84-1.70 (m, 2-H) 1.67-1.60 (m, 2-H)
11b 1.53-1.42 (m, 1-H) 1.48-1.34 (m, 4-H)
12 2.95 (dt, 7.4, 3.9, 1-H) 2.94 (dt, 8.1, 4.1, 1-H)
13 3.07 (dt, 8.2, 4.2, 1-H) 3.11 (dt, 8.4, 4.4, 1-H)
14a 2.24-2.11 (m, 1-H) 2.12 (ddd, 15.0, 4.6, 2.7, 1-H)
14b 2.00-1.82 (m, 1-H) 1.98 (dt, 14.8, 8.2, 1-H)
1H NMR of epothilone A standard was performed at 300 MHz in CDCl3 whereas the
Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), qn (quin
parts per million (ppm) and coupling constants J are given in Hz when appropriateconfirming the glucosylation position at the C-7 hydroxyl
group. The NMR data were further supported by HR-
QTOF ESI-MS/MS analysis in which the fragment of
glucose conjugated at C-7 hydroxyl position was observed,
but we could not able to find the fragment of epothiloneepothilone A 7-O-β-D- glucoside
No. 1H NMR of epothilone
A standard
1H NMR of epothilone
A 7-O-β-D glucoside
15 5.46 (dd, 8.9, 2.6, 1-H) 5.47 (ddd, 8.5, 2.6, 1.1, 1-H)
17 6.63 (dd, 1.8, 1.0, 1-H) 6.63 (dd, 2.1, 1.1, 1-H)
19 7.01 (s, 1-H) 7.26 (s, 1-H)
21 2.73 (s, 3-H) 2.71 (s, 2-H)
22 1.13 (s, 3-H) 1.16 (t, 6.4, 3-H)
23 1.40 (s, 3-H) 1.33 (s, H-23)
24 1.21 (d, 6.9, 3-H) 1.30 (d, 6.9, 3-H)
25 1.04 (d, 7.0, 3-H) 1.07 (d, 6.9, 3-H)
27 2.12 (d, 1.3, 3-H) 2.09 (d, 1.3, 3-H)
1' No proton 4.49 (d, 7.8, 1-H)
2' No proton 3.41 (t, 9.0, 1-H)
3' No proton 3.52-3.47 (m, 2-H)
4' No proton 3.38-3.34 (m, 1-H)
5' No proton 3.52-3.47 (m,2-H)
6a' No proton 3.88 (dd, 11.8, 2.4, 1-H)
6b' No proton 3.71 (dd, 11.8, 5.5, 1-H)
1H NMR of epothilone A glucoside was determined at 900 MHz in CD3OD.
tet), m (multiplet) and br (broad) if necessary. Chemical shifts are reported in
.
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Figure S3A). Thus, the product was elucidated as epothi-
lone A 7-O-β-D-glucoside, which is a novel glucoside
derivative of epothilone that has not been reported.
Zhao and his group have successfully characterized a
pentoside of epothilone A as epothiloneoside A in 2010
from Sorangium cellulosum So0157-2 (PCT/CN2008/
001946) strain culture, and the glycosylated compound
was detected as attachment of sugar in C-3 hydroxyl pos-
ition with a molar mass of 625.29. The compound was de-
termined to be 3-O-α-D-ribofuranosyl epothilone A (Zhao
et al. 2010) beside this no other reports are available about
glycosylated analogues of epothilone A.
Time-dependent study of the glucosylation reaction
A glycosylation reaction with epothilone A and UDP-D-
glucose was conducted as described above to identify
the incubation time needed for maximum conversion
of epothilone A to epothilone A 7-O-β-D-glucoside and to
find out the stability of thus produced glucoside derivative
in the reaction mixture. Samples were taken out at different
times (0 h, 2 h, 4 h, 5 h, 7 h, and 8 h) and were subjected
to UPLC-PDA at an absorbance of 249 nm. Under the 8 h
reaction mixture analyses, the maximum glucoside con-
version was achieved between 3 h to 5 h of incubation
(25.55–25.56%) at 37°C, whereas product formation de-
clined after 5 h (Figure 5). We did not achieve a signifi-
cantly higher conversion rate after extending the incubation
period. Instead, the product was degraded when the incu-
bation time was increased. Two possible reasons explain
the decreasing concentration of epothilone A 7-O-β-D-
glucoside in the reaction mixture with a longer incubation.
The first could be deglycosylation of epothilone A 7-O-β-
D-glucoside to epothilone A and UDP-D-glucose, as this
property of YjiC has been previously characterized in our
study. A second reason could be the thermodynamic
instability of the compound in the reaction mixture.
Enzymatic synthesis of diverse epothilone A glycosides
After confirming production of epothilone A 7-O-β-D-glu-
coside, we attempted enzymatic glycosylation of epothilone
A using various NDP-D/L-sugars. Most of the NDP-sugars
used for the reaction were rare sugars. Thus, identical reac-
tions were carried out varying only the NDP-sugar donor at
37°C. UPLC-PDA coupled with HR-QTOF ESI-MS/MS
analyses (Figures 2 and 3) revealed the presence of glyco-
sylated products in all of the independent reactions of YjiC
with epothilone A and UDP-D-galactose, TDP-D-2-deoxy-
glucose, GDP-L-fucose, and TDP-L-rhamnose. Because of
the lack of excess availability of NDP-D/L-sugars, their long
enzymatic synthesis process and very low conversion rate
of epothilone A to respective glycosides (Figure 2), we were
unable to characterize those products by NMR analysis.
Because the structurally elucidated epothilone A glucosideshowed that the C-7 hydroxyl position of epothilone A
is prominent for glycosylation by YjiC, other NDP-D/
L-sugar reaction mixtures analyzed by high resolution exact
mass spectra (Figure 3) confirmed the products as epothi-
lone A 7-O-β-D-galactoside (tR:4.15 min, [EpoAGal +H]
+
m/z+: calculated exact mass 656.3105 for C32H50NO11S,
found 656.3265), epothilone A 3,7-O-β-D-digalactoside
(tR:3.78 min, [EpoADigal + H]
+ m/z+: calculated exact
mass 818.3633 for C38H60NO16S, found 818.3639)
(Figure 3(C and D)), epothilone A 7-O-β-D-2-deoxyglu-
coside (tR:3.46 min, [EpoA2-deoxyglc + H]
+ m/z+: calculated
exact mass 640.3155 for C32H50NO10S, found 640.3226)
(Figure 3(B)), epothilone A 7-O-β-L-fucoside (tR:4.72 min,
[EpoAfuc + H]
+ m/z+: calculated exact mass 640.3155 for
C32H50NO10S, found 640.3170) (Figure 3(E)), and epothi-
lone A 7-O-β-L-rhamnoside (tR:3.67 min, [EpoArhm +H]
+
m/z+: calculated exact mass 640.3155 for C32H50NO10S,
found 640.3147) (Figure 3(F)). Thus produced epothilone
glycosides and their position of glycosylation were also
further confirmed by HR-QTOF ESI-MS/MS analyses
(Additional file 1: Figure S3 (B-E)). The MS/MS fragmenta-
tion of each epothilone A glycosides showed the presence
of prominent fragment of epothilone A with respective
sugars attached at C-7 hydroxyl position. The fragment
of sugar attached at the C-3 hydroxyl position was not
observed in ESI-MS/MS spectra of all glycoside derivatives.
The structural elucidation of epothilone A 7-O-β-D-gluco-
side by NMR studies and HR-QTOF ESI-MS/MS analysis
of all epothilone A glycosides proved that YjiC regioselec-
tively glycosylate at 7-hydroxyl position of epothilone A.
Although all of the produced epothilone A glycosides
were monoglycosides, a digalactoside derivative (epothilone
A 3, 7-O-β-D-digalactoside) was also produced using UDP-
D-galactose as the sugar donor (Figure 6).
Discussion
Interest in epothilones immediately soared when they were
tested and found to have extraordinary inhibitory effects on
cell proliferation and cell death in paclitaxel-resistant tumor
cell lines at up to 5,000-fold lower concentrations than that
of taxol (Carlomagno et al. 2003). Drugs that target micro-
tubules are the most commonly prescribed anticancer
therapeutics in current clinical practice. Epothilones bear
similar potency and were classified as a new class of anti-
microtubule agents that share the equipotent structural
and functional properties with taxanes among which few
have already passed preclinical studies as cancer therapeutic
agents (Zhao et al. 2010; Goodin et al. 2004). Ixabepilone, a
semisynthetic analog of epothilone B, was approved by the
US Food and Drug Administration in October 2007 to
treat metastatic or locally advanced breast cancer as
monotherapy (Donovan and Vahdat 2008).
Microtubules play a crucial role in cellular processes such
as cell motility, intracellular trafficking, cell division, and
Figure 5 The time dependent study of epothilone A glucosylation. The enzymatic conversion of epothilone A to epothilone A 7-O-β-D-glucoside
was determined at different time intervals. The error bars represent the standard deviation of three independent experiments.
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http://www.amb-express.com/content/4/1/31cell maintenance. Thus, current compounds targeting
microtubules are being developed as cancer chemother-
apeutic agents (Bollag et al. 1995). The microtubule target-
ing compounds engage at the mitotic spindle checkpoint
where they block cell cycle progression at mitosis ultimately
leading to apoptosis (Bhat and Setaluri 2007). Nevertheless,
epothilones were originally described as natural product
fungicidal macrolides (Hofle and Reichenbach 2005). How-
ever, later studies revealed the microtubule polymerization
property at submicromolar concentrations and soon theirFigure 6 Glycosylation reaction of epothilone A catalyzed by the YjiC
five different sugar moeities (glucose, galactose, 2-deoxyglucose, rhamnose
analogues. All the identified epothilone A glycosides are novel compoundspotency was verified to replace paclitaxel (Goodin et al.
2004). Epothilone arrests cells at the mitotic G2/M tran-
sition phase (a rapid cell growth and protein synthesis
period) at low nanomolar concentrations eventually leading
to apoptosis during mitosis (Harle and Bechthold 2009).
Since the discovery of such cytotoxic potential bearing
microtubule-stabilizing agents, total synthesis has been
a challenge to most organic chemists (He et al. 2001). The
reason is an adequate supply of epothilones as healing
agents for clinical studies. Similar class of microtubulesenzyme with diverse NDP-D/L-sugars. Epothilone A is coupled with
, and fucose) to generate six diverse epothilone A glycoside
.
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http://www.amb-express.com/content/4/1/31stabilizing anticancer drugs such as discodermolide
(ter Haar et al. 1996), elutherobin (Long et al. 1998), sar-
codictyins A and B (Hamel et al. 1999), and laulimalide
(Mooberry et al. 1999) have been reviewed by Karl-Heinz
Altmann in 2001.
Taxens are considered to be first-line option for
metastatic breast cancer, but their utility was compromised
because of resistivity (Cortes et al. 2012). Thus, epothilone
A was selected for in vitro glycosylation in the current
study because it has high demand in the cancer therapeutic
development possessing high cytotoxic effects in taxane
sensitive cell lines including P-glycoprotein overexpression
(Cortes et al. 2012). Cytotoxic effects of epothilones with
diverse human cancer cell line including lung cancer
cell line (NCI-H460) (Kim et al. 2003), ovarian cancer
cell line (SKOV-3) (Rogalska et al. 2013), breast cancer cell
lines (Cheng et al. 2008), etc. have been reported in dose
dependent manner. However, six different analogues of
epothilones are in preclinical and clinical trials including
patupilone (epothilone A and B), ixabepilone (BMS247550),
BMS 310705, sagopilone (ZK-EPO), KOS-862 (epothilone
D), and KOS-1584, etc. where all of these compounds were
modified from major product of myxo-bacterium (epothi-
lone A and B) (Cheng et al. 2008). So, due to low water
solubility but high therapeutic value we hereby try to
synthesize the glucosyl analogues of epothilone A using
in vitro glycosylation approach. Six different glycoside
derivatives were successfully produced in the reaction cat-
alyzed by YjiC in the presence of diverse NDP-D/L-sugars
as explained in result section. Maximum glucoside con-
version rate was determined from the time dependent
study of epothilone A coupled with UDP-D-glucose. Ap-
proximately 26% glucoside was achieved in between 3 h to
5 h of incubation time at 37°C. As explained in the result
section, after 5 h the catalytic activity of YjiC preferred
reverse direction while extending the incubation time as
the product formation was declining. Another reason is
the structural rigidity of the aglycon which results in low
substrate availability to the glycosyltransferase (Wu et al.
2012 and Richard et al. 1999). The exact catalytic activity
of the diverse substrate flexible bacterial glycosyltransfer-
ase, YjiC has not been determined so far. So this could be
one advantage in modification of diverse antibiotics or
other natural products with different glycosylation approach.
The validated in vitro glycosylation reaction of epothilone
A with diverse sugar donors and new putative glucoside
peak(s) formation during UPLC-PDA analysis were fur-
ther verified through high resolution ESI MS/MS analysis
revealed the successive generation of six different glycosyl-
ated analogues. Epothilone A glucoside was referenced for
further (1-D and 2-D) NMR analysis which ultimately ex-
posed the C-7 hydroxyl position sugar conjugated com-
pound as epothilone A 7-O-β-D-glucoside. This concludes
the C-7 hydroxyl position of epothilone A is regiospecificfor the glycosylation because as we can see the C-3 hy-
droxyl position is much hindered by the presence of two
keto-groups in parallel position.
Engineering the sugar moiety in natural products has
always generated novel therapeutic drugs and enhanced
their parental properties based on structural, functional,
and cell recognition (Desmet et al. 2012). Thus, these
modified novel glycosyl analogues of epothilone A could
be the new drugs for treating cancers in the future. In
the near future, different glycosylated analogues of
epothilone A with improved efficacy will be exploited to
develop further clinical applications. But additional experi-
mental evidence including biological activities will certainly
help to describe the structural and functional efficacy of
newly synthesized derivatives. The approach of produ-
cing glycodiversified compounds definitely adds signifi-
cance to the development of novel drugs for treating
various diseases including cancer. As the yield of novel
compounds is too low at the current stage, engineering of
the YjiC glycosyltransferases is essential for improved cata-
lytic efficiency of the enzyme to industrially target epothi-
lone A glycoside derivatives.
Additional file
Additional file 1: 1-dimensional 1H-NMR and 13C- NMR of epothilone
A standard. 13C-NMR and 2-dimensional NMR analyses of epothilone A
7-O-beta-D-glucoside. HR-QTOF ESI-MS/MS analysis of diverse Epothilone A
glycosides.
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